ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. Financials - Benzinga

ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc.

ALPMYOTCPK

Trade with Public

Trade with Public

$15.16

0.120.8%

At close: Aug 25, 5:00 PM EST

Overview NewsFinancialsSentiment Ownership Compare

ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. Financials

ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. (ALPMY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why

Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, and upbeat earnings boost outlook.

Vandana Singh

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.

Vandana Singh

Stocks Rise As Investors Welcome JPMorgan's Purchase Of First Republic's Assets; Treasury Yields Rise As Banking Crisis Recedes

Shanthi Rexaline

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)

Shanthi Rexaline

The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)

Shanthi Rexaline